An MRI-guided HIFU-triggered wax-coated capsule for supertargeted drug release: a proof-of-concept study

Abstract

Background Externally controlling and monitoring drug release at a desired time and location is currently lacking in the gastrointestinal tract. The aim of the study was to develop a thermoresponsive wax-coated capsule and to trigger its release upon applying a magnetic resonance imaging (MRI)-guided high-intensity focused ultrasound (HIFU) pulse. Methods Capsules containing a lyophilised gadolinium-based contrast agent (GBCA) were coated with a 1:1 (mass/mass) mixture of lanolin and cetyl alcohol (melting point ≈43 °C) and exposed to simulated gastric and intestinal fluids (United States Pharmacopoeia) at 37 °C for 2 and 24 h, respectively. In a HIFU gel phantom, wax-coated capsules ( n = 3) were tracked based on their T1- and T2-hypointensity by 1.5-T T1- and T2-weighted MRI pre- and post-exposure to an MRI-guided HIFU pulse. Results Lanolin/cetyl alcohol-coated capsules showed high resistance to simulated gastrointestinal fluids. In a gel phantom, an MRI-guided HIFU pulse punctured the wax coating, resulting in the hydration and release of the encapsulated lyophilised GBCA and yielding a T1-hyperintense signal close to the wax-coated capsule. Conclusion We provide the proof-of-concept of applying a non-invasive MRI-guided HIFU pulse to actively induce the disintegration of the wax-coated capsule, and a method to monitor the release of the cargo via T1-weighted MRI based on the hydration of an encapsulated lyophilised GBCA. The wax-coated capsule platform enables temporally and spatially supertargeted drug release via the oral route and promises to address a currently unmet clinical need for personalised local therapy in gastrointestinal diseases such as inflammatory bowel diseases and cancer. Electronic supplementary material The online version of this article (10.1186/s41747-019-0090-9) contains supplementary material, which is available to authorized users.

pH-Responsive nanocomposite fibres allowing MRI monitoring of drug release

“…This can ensure that patients are given an appropriate dose to treat their disease without experiencing dangerous or unpleasant side effects. Unlike previous work, 26,41 our fibres display pH-responsive relaxation behaviour around the physiological pH, potentially allowing them to be used to image abnormal local microenvironments in intestinal and colon cancer.…”

Stimuli-Responsive Gold Nanocages for Cancer Diagnosis and Treatment

“…In particular, high-intensity focused ultrasound (HIFU) has been found to be a promising trigger for controlling drug release due to its ultra-high energy and millimeter-scale focusing ability [ 74 , 75 , 76 ]. In addition, HIFU can penetrate deeper into soft tissues than NIR light, so it may be a more effective external trigger for rapid and on-demand drug release [ 77 ].…”

Addressing intimate partner violence during the COVID-19 pandemic and beyond: how radiologists can make a difference

“…Radiologists have been making outstanding contributions to the health of physically abused children [30], and we believe that they can have a similarly positive influence on the lives of IPV victims. We acknowledge the "invisible wall" between diagnostic radiologists and patients, but we believe that radiologists will become more patient-centered in the future and contribute to patient care by directly engaging with their patients, particularly as artificial intelligence-based systems become more established [31][32][33][34][35][36][37][38][39][40][41][42][43][44]. As radiologists move beyond the reading room and join the multidisciplinary team providing direct care to the patient, they may choose to volunteer to handle IPV cases, especially if they are trained to handle the complexities of these conversations.…”